Financial Performance - As of September 30, 2024, Traws Pharma had cash, cash equivalents, and short-term investments of approximately $5.4 million, down from $20.8 million at December 31, 2023[6]. - The net loss for Q3 2024 was $8.5 million, or $8.81 per share, compared to a net loss of $4.7 million, or $5.64 per share, for the same period in 2023[9]. - Traws Pharma's accumulated deficit increased to approximately $619.2 million as of September 30, 2024, compared to $482.6 million at the end of 2023[14]. - The company reported total liabilities of $10.97 million as of September 30, 2024, down from $12.01 million at the end of 2023[14]. Research and Development - Research and development (R&D) expenses for Q3 2024 totaled $5.1 million, compared to $2.5 million for the same period in 2023, reflecting a significant increase due to the initiation of Phase 1 studies[7]. - Traws Pharma is advancing its antiviral programs, with Phase 2 studies for ratutrelvir and tivoxavir marboxil expected to commence in 2025[2]. - Phase 1 data for ratutrelvir indicates it can be dosed without ritonavir, showing no treatment-related adverse events and consistent plasma drug levels[3]. - Phase 1 data for tivoxavir marboxil supports its potential as a single-dose treatment for influenza, maintaining plasma drug levels above the EC90 for over five days[4]. Operating Expenses - General and administrative (G&A) expenses for Q3 2024 were $3.5 million, up from $2.7 million in Q3 2023, primarily due to increased professional and consulting fees[8]. - Traws Pharma's total operating expenses for Q3 2024 were $8.6 million, compared to $5.1 million for the same period in 2023[15].

Core Insights - Traws Pharma is advancing its clinical pipeline with promising Phase 1 data for its antiviral programs targeting COVID-19 and influenza, indicating potential for best-in-class treatments [2][3] Clinical Development - Ratutrelvir shows potential as a once-a-day, single-drug, 10-day treatment for COVID-19 without the need for ritonavir, demonstrating lower likelihood of clinical rebound and good tolerability [1][3] - Tivoxavir marboxil is positioned as a one-time treatment for influenza, including pandemic strains, with favorable pharmacokinetic profiles and tolerability [1][3] Upcoming Milestones - Phase 2 clinical proof of concept studies for both ratutrelvir and tivoxavir marboxil are expected to commence in 2025 [2][3] Financial Performance - As of September 30, 2024, Traws Pharma reported cash and cash equivalents of approximately $5.4 million, a decrease from $20.8 million at December 31, 2023 [5] - Research and development expenses for Q3 2024 totaled $5.1 million, up from $2.5 million in Q3 2023, primarily due to Phase 1 study costs [6] - General and administrative expenses increased to $3.5 million in Q3 2024 from $2.7 million in Q3 2023, driven by higher professional fees [7] - The net loss for Q3 2024 was $8.5 million, compared to a net loss of $4.7 million in the same period of 2023 [8] Company Overview - Traws Pharma is a clinical stage biopharmaceutical company focused on developing oral small molecule therapies for respiratory viral diseases and cancer [9][10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |--------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |-------------------------------------------------- ...

Table of Contents | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------| | | UNITED STATES SEC ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) 18940 Registran ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of incor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) | --- | |--------------------------------------| | | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of ...